The online version of this article (https://doi.org/10.1007/s12325-019-00946-1) contains supplementary material, which is available to authorized users.
To view enhanced digital features for this article go to https://doi.org/10.6084/m9.figshare.7893254.
Assess the cost-effectiveness (US healthcare payer perspective) of sarilumab subcutaneous (SC) 200 mg + methotrexate versus conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) or targeted DMARD + methotrexate for moderate-to-severe rheumatoid arthritis (RA) in adults with inadequate response to methotrexate.
Microsimulation based on patient profiles from MOBILITY (NCT01061736) was conducted via a 6-month decision tree and lifetime Markov model with 6-monthly cycles. Treatment response at 6 months was informed by a network meta-analysis and based on American College of Rheumatology (ACR) response. Responders: patients with ACR20 response who continued with therapy; non-responders: ACR20 non-responders who transitioned to the subsequent treatment. Utilities and quality-adjusted life-years (QALYs) were estimated via mapping 6-month ACR20/50/70 response to relative change in Health Assessment Questionnaire Disability Index score (short term) and based on published algorithms (long term). Direct costs considered drugs (wholesale acquisition costs), administration and routine care.
Lifetime QALYs and costs for treatment sequences on the efficiency frontier were 3.43 and $115,019 for active csDMARD, 5.79 and $430,918 for sarilumab, and 5.94 and $524,832 for etanercept (all others dominated). Sarilumab was cost-effective versus tocilizumab and csDMARD (incremental cost-effectiveness ratios of $84,079/QALY and $134,286/QALY). Probabilistic sensitivity analysis suggested comparable costs and slightly improved health benefits for sarilumab versus tocilizumab, irrespective of threshold.
In patients with moderate-to-severe RA, sarilumab 200 mg SC every 2 weeks + methotrexate can be considered a cost-effective treatment option, with lower costs and greater health benefits than alternative treatment sequences (+ methotrexate) beginning with adalimumab, certolizumab, golimumab and tofacitinib and below commonly accepted cost-effectiveness thresholds against tocilizumab + methotrexate or csDMARD active treatment.
Sanofi and Regeneron Pharmaceuticals, Inc.
Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24. CrossRef
Shah A, St Clair W. Rheumatoid arthritis. In: Kasper D, Fauci A, Hauser S, et al., editors. Harrison’s principles of internal medicine. 19th ed. New York: McGraw-Hill Education; 2015.
Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis Rheum. 2010;62:2569–81. CrossRef
Davis S, Stevenson M, Tappenden P, et al. Cost-Effectiveness Modelling Using Patient-Level Simulation [Internet]. London: National Institute for Health and Care Excellence (NICE); 2014. NICE DSU Technical Support Document No. 15. 2014. https://www.ncbi.nlm.nih.gov/books/NBK310370/. Accessed 13 Nov 2017.
Institute for Clinical and Economic Review. Targeted immune modulators for rheumatoid arthritis: effectiveness and value. Evidence report. 2017. https://icer-review.org/wp-content/uploads/2016/08/NE_CEPAC_RA_Evidence_Report_FINAL_040717.pdf. Accessed 28 Sept 2017.
Caro JJ, Briggs AH, Siebert U, et al. Modeling good research practices—overview: a report of the ISPOR-SMDM modeling good research practices task force-1. Med Decis Mak. 2012;32:667–77. CrossRef
Huynh T, Proudfoot C, Chen C, et al. Network meta-analysis of the efficacy and safety of sarilumab monotherapy and combination therapy in rheumatoid arthritis patients with intolerance or inadequate response to disease-modifying antirheumatic drugs. J Manag Care Spec Pharm. 2017;23:S75.
Stevenson M, Archer R, Tosh J, et al. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation. Health Technol Assess. 2016;20:1–610. PubMedPubMedCentral
Bruce B, Fries JF. The Health Assessment Questionnaire (HAQ). Clin Exp Rheumatol. 2005;23:S14–8. PubMed
Malottki K, Barton P, Tsourapas A, et al. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation. Health Technol Assess. 2011;15:1–278. CrossRefPubMedPubMedCentral
National Institute for Health and Care Excellence. Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis, NICE technology appraisal guidance [TA130]. 2007. https://www.nice.org.uk/guidance/ta130. Accessed 21 Oct 2017.
Boggs R, Sengupta N, Ashraf T. Estimating health utility from a physical function assessment in rheumatoid arthritis (RA) patients treated with adalimumab (D2E7). Value in Health. 2002;5:452–3. CrossRef
Arias E. United States Life Tables, 2011. Natl Vital Stat Rep. 2015;64:1–63. PubMed
Wailoo A, Brennan A, Bansback N, et al. Modeling the cost effectiveness of etanercept, adalimumab and anakinra compared to infliximab in the treatment of patients with rheumatoid arthritis in the Medicare program. 2006. http://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Reports/Research-Reports-Items/CMS1202288.html. Accessed 13 Nov 2017.
Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.
Anderson JL, Heidenreich PA, Barnett PG, et al. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:2304–22. CrossRefPubMed
Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. New York: Oxford University Press; 2006.
World Health Organization. Making choices in health: WHO guide to cost-effectiveness analysis 2003. http://www.who.int/choice/publications/p_2003_generalised_cea.pdf. Accessed 13 Nov 2017.
National Institute for Health and Care Excellence. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor. Technology appraisal guidance [TA195]. 2010. https://www.nice.org.uk/guidance/ta195. Accessed 28 Sept 2017.
Favalli EG, Biggioggero M, Marchesoni A, et al. Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies. Rheumatology (Oxford). 2014;53:1664–8. CrossRef
- Economic Evaluation of Sarilumab in the Treatment of Adult Patients with Moderately-to-Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs
- Springer Healthcare
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II